Phase II Multi-institutional Proof of Concept Single-arm Trial of Nivolumab in the Treatment of Patients With Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Proof of concept; Therapeutic Use
- 08 Nov 2019 Status changed from withdrawn prior to enrolment to discontinued.
- 19 Aug 2019 Planned End Date changed from 1 Dec 2022 to 30 Jun 2019.
- 19 Aug 2019 Planned primary completion date changed from 1 Oct 2020 to 30 Jun 2019.